Barson builds businesess.

Barson Corporation is a private company that specializes in forming, growing, and financing highly unique, technically advanced businesses. Barson takes both majority and minority positions in their client-customers, and provides strategic consulting services and select corporate services, including strategic management support, initial financing, marketing and branding, operational logistics, HR, project management, and more. Originally focused on high-performance surfaces and materials, Barson has progressed into the biotechnology and software spaces.

Current Investments:

  • HIMED
    Bioceramics manufacturing and surface treatment

  • MERCURY BIO
    Biotechnology and in-vivo drug delivery

  • BIG GIANT DONUT
    No-code software for app building

  • FRAME BIO
    Biotechnology focused on the skin-bone axis

Previous Investments:

  • HITEMCO
    High-performance surfaces for aerospace

  • SAVSU TECHNOLOGIES
    Storage, shipping, and information systems for cell and gene therapies

  • HITEMCO SOUTHWEST
    High-performance surfaces

Himed LLC

Formed in 1991, Himed is an internationally recognized manufacturer of advanced calcium phosphate-based biomaterials, coatings, abrasives, and surface treatments for orthopedic and dental implant applications. The company’s ISO 13485-certified and FDA-registered New York facility supplies high-purity calcium phosphate compounds in a wide variety of forms, optimized for specific resorption rates, and manufactures biocompatible abrasives for residue-free surface enhancement of implants.

Recent expansions include capabilities in additive manufacturing for 3D-printed orthopedic and dental implants, with contract research and prototyping services available through the new Bioceramics Center of Excellence™ (BCoE). Himed delivers high-performance biomaterials and implant coatings to medical device manufacturers across six continents, and continues to shape the future of regenerative medicine and implantology by integrating biomaterial expertise, proprietary process engineering, and advanced surface modification techniques that meet the evolving demands of healthcare and medical research.

Himed is at the forefront of innovation in biomaterials, offering:

  • Medical-grade hydroxyapatite (HA) for dental, orthopedic, and spinal implants—available in various forms and applied via plasma spray for enhanced osseoconductive performance.

  • Custom calcium phosphate compounds such as biphasic blends for tailored bone healing applications.

  • Calcium phosphate forms for research and testing, such as HA enamel-like discs and teeth

  • MCD Apatitic Abrasive, a resorbable blast media for titanium, titanium alloy, stainless steel, and PEEK surfaces, enabling uniform micro-porosity and natural cell adhesion without embedded contaminants.

  • Surface treatment technologies including proprietary MATRIX® HA coatings, MATRIX MCD®, and MATRIX Dual® micro-abrasive blasting processes.

  • R&D and prototyping through the Bioceramics Center of Excellence™ (BCoE), supporting rapid development and scale-up of 3D-printed calcium phosphate devices with advanced bioinks and next-generation ceramic printers.

  • Biomaterials characterization and materials testing—including scanning electron microscopy (SEM), X-ray diffraction (XRD), energy-dispersive X-ray spectroscopy (EDS/EDX), ICP elemental analysis, FTIR spectroscopy, particle size and moisture analysis, mechanical and abrasion testing, and skeletal density measurements.

Mercury Bio Inc.

Formed in 2020, Mercury Bio is a biotechnology innovator specializing in next-generation biomolecular drug delivery systems. Driven by breakthroughs in genomic science, the company has developed a proprietary platform that enables highly targeted, cell-specific, in-vivo delivery of large- and small-molecule therapeutics. Rather than relying on traditional encapsulation methods, Mercury Bio engineers naturally occurring yeast extracellular vesicles (yEV™) to encapsulate therapeutics and display targeting mechanisms—ensuring potent, precise delivery only to desired cells, while reliably bypassing immune system reactions. Mercury Bio has already demonstrated that yEV™ can transport proteins, nucleic acids, and small-molecule drug payloads to nearly every organ group in the body.

Mercury Bio maintains a state-of-the-art laboratory at its New Mexico headquarters, supporting its own R&D and offering collaborative development, biomaterials prototyping, and joint research partnerships with leading medical and biomaterials firms. The company’s analytical capabilities encompass characterization of vesicle formulations, cellular targeting, drug encapsulation efficiency, and controlled release kinetics—providing actionable data for pharmaceutical development, regulatory filings, and quality assurance.

Mercury Bio’s technology directly addresses major barriers in modern medicine:

Protein, Nucleic Acid, and Small-Molecule Drug Delivery: By using engineered EVs with cell-targeting features, Mercury Bio’s technology can achieve appropriate potency, enhanced bioavailability, and drastically reduced off-target side effects.

Platform Versatility: The system delivers a range of payloads—including RNA, peptides, proteins, and small-molecule drugs—while supporting tailored release profiles for complex medical needs.

Clinical Impact: These advances allow drug developers and researchers to accelerate product development, reduce regulatory and manufacturing obstacles, and improve patient outcomes across therapeutic categories including cancer, viral diseases, and advanced orthopedics.

Big Giant Donut LLC

Big Giant Donut is a forward-thinking software company committed to modernizing the landscape of no-code programming and database solutions. In September 2022, the company acquired the legacy Helix programming system, a groundbreaking database solution launched in 1983, which pioneered the no-code movement for Macintosh. With this acquisition, BGD is reimagining Helix for the 21st century as a tool that combines true no-code ease of use with unprecedented power, adaptability, and Web3 functionality.

Backed by a passionate team that includes the original Helix developers, Big Giant Donut combines decades of technical expertise with modern software, empowering a new generation of businesses, creatives, small teams, and software developers with intuitive tools for swift and effective custom application development.

Frame Bio LLC

Formed by Barson in 2024 to encapsulate and expand a cutting-edge research agreement between Himed and Mercury Bio, Frame Bio uses Mercury Bio’s yEV™ platform to advance new therapies that target conditions affecting the skin-bone axis. Frame Bio’s research acknowledges the intricate relationship between skin and bones, which have shared cellular origins, a shared reliance on collagen, and have common physiological pathways.

Their pioneering research focuses on three key areas: collagen regeneration, accelerated bone healing, and inflammation reduction. The company is particularly excited about its lead candidate in the pipeline, an mRNA therapy designed to promote collagen regeneration in challenging areas such as wounds, skin, and hard-tissue damage.

Contact Barson